Navigation Links
InterMune Reports First Quarter 2011 Financial Results and Business Highlights
Date:4/28/2011

60;Lower R&D expenses reflect timing of the preparation of regulatory filings related to pirfenidone, and the divestiture of danoprevir in October of 2010.

General and administrative (G&A) expenses were $17.6 million in the first quarter of 2011, compared with $15.1 million in the same period a year earlier.  The net increase in G&A expenses is primarily attributed to costs related to preparation for the commercialization of Esbriet, including establishment of a European infrastructure and pre-launch marketing expenses, offset by a significant decrease in this quarter versus the same quarter last year in U.S. infrastructure and pre-launch marketing expense.

The net loss for the first quarter of 2011 was $32.1 million, or $0.57 per share, compared with a net loss of $34.1 million, or $0.66 per share, in the first quarter of 2010.  

As of March 31, 2011, InterMune had cash, cash equivalents and available-for-sale securities of approximately $254.3 million.

Conference Call and Webcast DetailsInterMune will host a conference call today at 8:30 a.m. EDT to discuss business highlights and  financial results for the first quarter of 2011.  Interested investors and others may participate in the conference call by dialing 888-567-5125 (U.S.) or 706-643-9223 (international), conference ID# 62213806.  A replay of the webcast and teleconference will be available approximately three hours after the call.

To access the webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 62213806.  The webcast will remain available on the
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. InterMune to Present at Canaccord Adams Conference
2. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
3. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
4. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
5. InterMune to Release Third Quarter 2008 Financial Results on November 6
6. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
7. InterMune to Present at Deutsche Bank Biotech Boston Confab
8. InterMune to Present at J.P. Morgan Healthcare Conference
9. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
10. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
11. InterMune Announces Issuance of U.S. Patent for ITMN-191
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... , April 30, 2015  Roka Bioscience, Inc. (NASDAQ: ... providing advanced testing solutions for the detection of foodborne ... the first quarter of 2015 on May 7, 2015 ... Roka Bioscience will also host a conference call at ... discuss its first quarter financial results. During the conference ...
(Date:4/30/2015)... South San Francisco, CA (PRWEB) April 30, 2015 ... revenues for the first quarter of 2015 were $4.4 million, ... The net loss for the first quarter was $8.9 ... compared to a net loss for the same period in ... diluted share. As of March 31, 2015, cash, cash equivalents ...
(Date:4/30/2015)... April 30, 2015 Nitto Avecia, ... announces its increased capacity and production capability to ... client variety and service fulfillment continues to drive ... improve process throughput capacities. , In ... installed downstream process equipment at its Milford, MA ...
(Date:4/30/2015)... -- The following is an open letter sent April 30, ... Corp (NYSE: CO ) from Jayhawk Capital. ... of China Cord Blood Corp (" China Cord ") will ... from Golden Meditech Holdings Co Ltd ("Golden Med"). Certainly, a ... Golden Med and Mr. Kam, the Chairman of both ...
Breaking Biology Technology:Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 2April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 3April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 4April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 5
... 1, 2008, at,8:30 a.m. Eastern/2:30 p.m. Central European/5:30 ... CTIC) management team will host a,conference call to ... to jointly market and develop Zevalin(R). The ... are also available for review on CTI,s,website, ...
... PARIS, November 28 ExonHit Therapeutics S.A.,(Alternext: ... announces today,the availability of its new SpliceArray(TM) ... disease. These SpliceArray(TM) products help our clients ... validation efforts. Using,our high resolution expression profiling ...
... leads a videocast discussion with top executives on the benefits ... , ... (PRWEB) November 28, 2008 ... Jim Miller, president of PharmSource Information Services Inc., moderated a ...
Cached Biology Technology:ExonHit Launches Mouse Genome SpliceArray(TM) for use in Human Disease Modeling Studies 2ExonHit Launches Mouse Genome SpliceArray(TM) for use in Human Disease Modeling Studies 3PharmSource President Moderates Videocast on Outsourcing to Asia at AAPS 2
(Date:3/23/2015)... -- In the 2014 fiscal year, irs.gov recorded over $100 ... accounts for a fraction of the estimated losses for ... $11 billion globally. The polygraph has traditionally been used ... Investor Mark Saint Juste along with former ... partnered to administer the test in a new way: ...
(Date:3/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has ... Strategic Business Report" report to their offering. ... US$ Thousands. The report provides separate comprehensive analytics for the ... , Europe , Asia-Pacific ... World. Annual estimates and forecasts are provided for ...
(Date:3/19/2015)... , March 19, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces its ... a news clip that aired this week on ... . In a segment "The Next Great Thing", ... ,a new way to pay, and ,a really big breakthrough ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... frozen. It,s grown in every state, and according to a ... adds up to a whopping $807 million per year industry ... business. Fresh market production of sweet corn in the ... annual volume marketed during winter months. Fresh sweet corn is ...
... today in an advanced online publication in the journal Nature ... the type of lung cancer that is the most common ... particular interest was a specific proto-oncogene called NKX2-1 that appears ... the most common cause of cancer deaths worldwide, ...
... Oakland, CA -- A new study led by Children,s ... is the first to suggest that a small protein ... could be used to accelerate the removal of iron ... help scientists develop new medications that dramatically improve the ...
Cached Biology News:How sweet is it? 2Tumor genome analysis unveils new insights into lung cancer 2Tumor genome analysis unveils new insights into lung cancer 3
A compact, high-speed single tube reader unit designed for benchtop 2D barcode reading. The unit can be used with all of ABgene's 2D barcoded tubes, including the 2ml CryoCode tube....
PTFE/red rubber septum silver aluminum seal ,11 mm seal diam. ...
... stops PCR carry-over contamination, which prevents ... PCR products from previous PCR amplifications ... which improves amplification ,Optimized for use ... GeneAmp instrument systems , The GeneAmp ...
... hydrolytic enzyme that catalyzes the conversion,of ... maltose, maltotriose and,dextrins. The level of ... human,body are of clinical importance,1-3 while ... for industry.4, The EnzChek Amylase Assay ...
Biology Products: